Change Country
Welcome to BelgiumWelcome
Please read the important information below before continuing to our website

The Lyxor ETFs on this website may be restricted for certain individuals or in certain countries pursuant to the national regulations applicable to those individuals or countries. It is therefore your responsibility to ensure that you are authorised to invest in the Lyxor ETFs on this website. 

 

If you are an investor in the United Kingdom, please go to www.lyxoretf.co.uk  

If you are an investor in the Netherlands, please go to www.lyxoretf.nl  

If you are an investor in Italy, please go to www.lyxoretf.it  

If you are an investor in Spain, please go to www.lyxoretf.es  

If you are an investor in Austria, please go to www.lyxoretf.at  

If you are an investor in Germany, please go to www.lyxoretf.de   

If you are an investor in Singapore, please go to www.lyxoretf.com.sg  

If you are an investor in Switzerland, please go to www.lyxoretf.ch  

If you are an investor in Belgium, please go to www.lyxoretf.be  

If you are an investor in Poland, please go to www.lyxoretf.pl 

If you are an investor in Norway, please go to www.lyxoretf.no

If you are an investor in Denmark, please go to www.lyxoretf.dk

If you are an investor in Luxembourg, please go to www.lyxoretf.lu

If you are an investor in Sweden, please go to www.lyxoretf.se

If you are an investor in Finland, please go to www.lyxoretf.fi

 

 

The Lyxor ETFs on this website are undertakings for collective investment in transferable securities (UCITS) (i) domiciled in France and approved by the Autorité des Marchés Financiers (AMF) or, (ii) domiciled in Luxembourg, approved by the Commission de Surveillance du Secteur Financier (CSSF) and authorised to market their units or shares in the French Republic in accordance with the notification procedure under Article 93 of Directive 2009/65/EC. Investors should note that the prospectuses of certain Lyxor ETFs under Luxembourg law that have been notified in accordance with this procedure are only available on the website in English. A French translation of these prospectuses can be obtained upon request by sending a letter to Lyxor International Asset Management (“Lyxor”) – 17 Cours Valmy, 92987 Paris La Défense, France.

 

The information on this website is not intended for persons or entities that are resident, located or registered in jurisdictions that are not authorised to distribute Lyxor ETFs. As a result, the information on this website does not constitute an offer or solicitation to buy or sell units or shares in these ETFs by anyone in any jurisdiction:

 

(a)   in which such an offer or solicitation is unauthorised;

(b)   in which Lyxor is not qualified to make such an offer or solicitation; or 

(c)   in which it is unlawful to make such an offer or solicitation.

 

In particular, the Lyxor ETFs on this website are not and will not be registered under the United States Securities Act of 1933, as amended. As such, they may not be offered or sold within the United States of America, except in specific cases where transactions are exempt from registration under the Securities Act. The ETFs listed on this website may not be sold to US citizens or transferred to the United States by any other means, unless this transaction is not subject to any specific registration under US law. 

 

Any person from a jurisdiction to which the above-mentioned restrictions apply should inform themselves of and observe these restrictions.

 

This website is intended for commercial purposes and is not regulatory in nature. Although the information provided has been drawn up on the basis of sources considered to be reliable, there is no guarantee that it is accurate, complete or relevant. Some of the information on this website is provided on the basis of market data collected at a specific time and may therefore vary over time. Lyxor advises investors to read the risk factors section of the prospectus and the key investor information document carefully. These documents can be found on the website.

 

The net asset value (“NAV”) of Lyxor ETFs may at any time be subject to considerable price fluctuations, which in some cases may lead to the loss of all of the capital invested. Investors should note that some ETFs may be sensitive to fluctuations in the exchange rate between their reference currency and that of the underlying index, as well as of the components of the underlying index.

 

Before investing in a Lyxor ETF, you should carry out your own risk analysis of the product from a legal, tax and accounting perspective, rather than basing your decision solely on the information provided. If necessary, you should consult your own advisers or any other qualified professional. 

 

Subject to compliance with the legal obligations by which they are bound, Lyxor or any entity within the same group shall not be held liable for any financial or other consequences of an investment in the product. 

 

 

By clicking on institutional or individual above, I confirm that I have read and understood the information provided herein, and that I am resident or registered in Belgium.

26 Feb 2019

China: Portfolio management in the year of the pig

It’s the Year of the Pig in China– which marks the end of the 12-year cycle of the animals of Chinese astrology. As such, it’s a perfect time to look back, learn from the past and prepare for the new cycle. Chanchal Samadder does exactly that.

Leaving 2018 behind


There’s no doubt 2018 was a challenging year in China, as policymakers wrestled with the country’s debt issues and tariffs and the trade war took their toll. Corporate defaults mounted, shadow banking was targeted and credit growth contracted.  To alleviate the burden on a private sector suddenly bereft of liquidity, officials designed specific tax-cutting polices rather than resort to a re-run of the large infrastructure plans seen in 2008 and 2015. The damage done by the trade tensions materialised in the latter part of the year as trade figures dropped and housing investment soured.  

For all that, the Chinese market is still young and, while there’s not much history on which to base a strategic view, there are plenty of reasons to be constructive on the country’s assets from a tactical, shorter-term perspective.

Controlling a slowdown

Why is that, given China’s economic growth could well slow further in H1? It’s not down to trade - even though the prospects of a temporary deal - or an extended truce - look greater, finding a lasting resolution will be challenging given the inescapable long-term rivalry between the US and China. Instead, the attraction is driven by policy. Growth should stabilise in H2, because there is more help on the way. We expect the PBOC to lower interbank lending rates and make further cuts to banks’ reserve requirements – which should free up more money for new lending to the private sector. China is also sticking with the large-scale tax cut strategy first deployed last year. The tax reduction programme for this year is set to be announced in March and could top 1.5 trillion yuan. The government has also outlined more tax breaks for small- and mid-sized businesses.


Chinese Credit growth suggests a stabilisation in activity
Chart 1

*Bloomberg economics China Credit Impulse: New credit as a % of GDP (Credit Impulse), provides a gauge of the boost that lending is providing to growth. The China Credit Impulse is calculated as: 12-month flow of total social finance, net of equity issuance, plus local government bond issuance, divided by the four quarter rolling sum of nominal GDP. Sources: Bloomberg, Macrobond, Lyxor International Asset Management/ Cross Asset Research, Data as at 31/01/2019. Past performance is not a reliable indicator of future results.

The problems are priced in

The market may not be at the distressed levels of end-2008, but things are still pretty ugly and Chinese equities remain well below their long-term averages. Equity valuations have in fact reverted to 2014 levels and many domestic Chinese firms have taken the hit already and issued profit warnings. On the listed market, earnings expectations are for low double-digit growth for both onshore and offshore markets – 13.6% and 12.0% respectively for the MSCI China and the Shanghai composite indices. We don’t, however, expect a deterioration from here. We suspect the worst has been priced-in and that targeted stimulus (tax relief, relaxing regulations for margin trading) has put a floor under earnings downgrades. 


China is too big to ignore…

The size of the China market means even more than its potential weighting in global indices. Inflows from non-residents recovered further to almost return to their long-term upward trend in 2018, thanks to a rebound in external banking debt and strong portfolio inflows facilitated by the fast-track opening-up of domestic capital markets. In fact. China attracted $50bn of equity inflows and $103bn of bond inflows in the first three quarters of last year - in the process surpassing full-year figures for 2017 - despite a slowing economy and a depreciating currency. Fast-track capital market liberalisation was the crucial ingredient. Portfolio inflows are likely to stay strong again this year, especially with MSCI likely to quadruple the inclusion ratio of China’s A shares in their bellwether emerging market benchmark, the MSCI Emerging Markets Index. All told, China A shares should account for around 15% of the index. Meanwhile, FTSE will include China in its EM indices for the first time. This should help fuel portfolio investments for few more years yet.


MSCI’s actions could be a substantial support for A-Share performance

  • On 31 May 2018, 233 China A Large Cap shares were added to the                                     MSCI Emerging market Index using a two-step inclusion process 
Chart 2

Source: MSCI, based on data used for MSCI ‘s May 2018 semi- annual index review. At a hypothetical 100% inclusion (which may or may not occur in the future), China would comprise 42% of the index, based on current market capitalization. All figures are approximate.

…and too disruptive to dismiss

China has become unavoidable for investors wanting exposure to the world’s new tech titans. According to the 2018 Kleiner Perkins Internet Trend report, nine of the top 20 internet companies in the world (by market valuation) are Chinese. On the listed market, China technology stocks have a weighting in global indices that is twice as high as the Japan and European technology sectors combined. China tech stocks have even become bigger than Korea, Taiwan and India combined (based on MSCI data). In our view, if you want to capture the opportunities on offer, there’s no better index than the MSCI China. Here’s why.

If, like us, you believe this index represents the truest and best reflection of China’s economy, why not consider investing in our ETF? With a TER of just 0.30% it is the cheapest Chinese equity ETF your money can buy.

Find out more about our Lyxor MSCI China UCITS ETF

Chinese astrology suggests those born in previous years of the pig are diligent, compassionate, and generous. They set goals and devote all their energy to achieving them. Calm when facing trouble, these “Pigs” handle things with care. They take responsibility to finish what they are engaged in. They are due some luck with their investments in 2019. Perhaps, if you adhere to those traits, you can expect the same! 

Sources: All views & opinions, Lyxor ETF Equity Strategy as at 7 February 2019, unless otherwise stated. Statements on Lyxor’s credentials vs. peers refer to the European UCITS ETF market only.


Risk Warning​

This document is for the exclusive use of investors acting on their own account and categorised either as “Eligible Counterparties” or “Professional Clients” within the meaning of Markets in Financial Instruments Directive 2014/65/EU. These products comply with the UCITS Directive (2009/65/EC). Société Générale and Lyxor International Asset Management (LIAM) recommend that investors read carefully the “investment risks” section of the product’s documentation (prospectus and KIID). The prospectus and KIID are available free of charge on www.lyxoretf.com, and upon request to client-services-etf@lyxor.com.

The products mentioned are the object of market-making contracts, the purpose of which is to ensure the liquidity of the products on the London Stock Exchange, assuming normal market conditions and normally functioning computer systems. Units of a specific UCITS ETF managed by an asset manager and purchased on the secondary market cannot usually be sold directly back to the asset manager itself. Investors must buy and sell units on a secondary market with the assistance of an intermediary (e.g. a stockbroker) and may incur fees for doing so. In addition, investors may pay more than the current net asset value when buying units and may receive less than the current net asset value when selling them. Updated composition of the product’s investment portfolio is available on www.lyxoretf.com. In addition, the indicative net asset value is published on the Reuters and Bloomberg pages of the product, and might also be mentioned on the websites of the stock exchanges where the product is listed.

Prior to investing in the product, investors should seek independent financial, tax, accounting and legal advice. It is each investor’s responsibility to ascertain that it is authorised to subscribe, or invest into this product. This document is of a commercial nature and not of a regulatory nature. This material is of a commercial nature and not a regulatory nature. This document does not constitute an offer, or an invitation to make an offer, from Société Générale, Lyxor Asset Management (together with its affiliates, Lyxor AM) or any of their respective subsidiaries to purchase or sell the product referred to herein.

Lyxor International Asset Management (LIAM), société par actions simplifiée having its registered office at Tours Société Générale, 17 cours Valmy, 92800 Puteaux (France), 418 862 215 RCS Nanterre, is authorized and regulated by the Autorité des Marchés Financiers (AMF) under the UCITS Directive (2009/65/EU) and the AIFM Directive (2011/31/EU). LIAM is represented in the UK by Lyxor Asset Management UK LLP, which is authorized and regulated by the Financial Conduct Authority in the UK under Registration Number 435658. Société Générale is a French credit institution (bank) authorised by the Autorité de contrôle prudentiel et de résolution (the French Prudential Control Authority).

Research disclaimer

Lyxor International Asset Management (“LIAM”) or its employees may have or maintain business relationships with companies covered in its research reports. As a result, investors should be aware that LIAM and its employees may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Please see appendix at the end of this report for the analyst(s) certification(s), important disclosures and disclaimers. Alternatively, visit our global research disclosure website www.lyxoretf.com/compliance.

Conflicts of interest 

This research contains the views, opinions and recommendations of Lyxor International Asset Management (“LIAM”) Cross Asset and ETF research analysts and/or strategists. To the extent that this research contains trade ideas based on macro views of economic market conditions or relative value, it may differ from the fundamental Cross Asset and ETF Research opinions and recommendations contained in Cross Asset and ETF Research sector or company research reports and from the views and opinions of other departments of LIAM and its affiliates. Lyxor Cross Asset and ETF research analysts and/or strategists routinely consult with LIAM sales and portfolio management personnel regarding market information including, but not limited to, pricing, spread levels and trading activity of ETFs tracking equity, fixed income and commodity indices. Trading desks may trade, or have traded, as principal on the basis of the research analyst(s) views and reports. Lyxor has mandatory research policies and procedures that are reasonably designed to (i) ensure that purported facts in research reports are based on reliable information and (ii) to prevent improper selective or tiered dissemination of research reports. In addition, research analysts receive compensation based, in part, on the quality and accuracy of their analysis, client feedback, competitive factors and LIAM’s total revenues including revenues from management fees and investment advisory fees and distribution fees.

Connect with us on linkedin